30 Week Parallel Group Comparison Study of Linagliptin + Pioglitazone (5+15, 5+30 and 5+45 mg) qd Versus Respective Monotherapies, Followed by a Comparison of 5mg+30mg and 5mg+45mg Versus Respective Monotherapies in Type 2 Diabetes for up to 54 Weeks
A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 936 participants.
Also called NCT01183013
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; double masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 936 participants
- Registry
-
NCT01183013 -
2008-008127-15
-
- Start date
- (registry gives no type)
- Primary completion
- (actual)
- Completion
- (actual)
- Results first posted
- Countries
- United States, Estonia, Germany, Latvia, Spain, United Kingdom
- Registry status
- Completed
Technical summary
Registry record NCT01183013. Randomized; double masking; primary purpose treatment. Start 2010-08 (registry gives no type); primary completion 2013-02 (actual). Results posted on 2014-04-21.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- 30 Week Parallel Group Comparison Study of Linagliptin + Pioglitazone (5+15, 5+30 and 5+45 mg) qd Versus Respective Monotherapies, Followed by a Comparison of 5mg+30mg and 5mg+45mg Versus Respective Monotherapies in Type 2 Diabetes for up to 54 Weeks
- Condition
- Diabetes Mellitus, Type 2
- Intervention (Drug)
- Pioglitazone 15 mg
- Intervention (Drug)
- Pioglitazone 45 mg
- Intervention (Drug)
- Pioglitazone 30 mg
- Intervention (Drug)
- Linagliptin 5mg / Pioglitazone 45 mg FDC
- Intervention (Drug)
- Linagliptin 5mg / Pioglitazone 30 mg FDC
- Intervention (Drug)
- Linagliptin 5mg
- Intervention (Drug)
- Linagliptin 5mg / Pioglitazone 15 mg FDC
- Lead sponsor
- Boehringer Ingelheim
- Collaborator
- Eli Lilly and Company
Record details
- Record id
cardio:ct-nct01183013- Content hash
e52aa85c23f9864ab767695534bf68ca48d02e0c4204ad8546b2abe6da2027d1